20240052423. METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF simplified abstract (Pfizer Inc.)
METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF
Organization Name
Inventor(s)
Joshua James Gruber of Dallas CA (US)
Melinda Telli of San Francisco CA (US)
METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240052423 titled 'METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF
Simplified Explanation
The patent application relates to a method of identifying metastatic tumors with mutations in homologous recombination pathway genes that are sensitive to treatment with talazoparib.
- Determining a homologous recombination deficiency score from a biopsy of the metastatic tumor.
- Administering talazoparib if the homologous recombination deficiency score is at least 33%, and the mutation is not germline BRCA1 or BRCA2.
- Potential Applications:**
- Personalized medicine for cancer treatment. - Targeted therapy for metastatic tumors with specific mutations.
- Problems Solved:**
- Identifying the most effective treatment for metastatic tumors with mutations in homologous recombination pathway genes. - Avoiding unnecessary treatments that may not be effective.
- Benefits:**
- Improved treatment outcomes for patients with metastatic tumors. - Reduced side effects from ineffective treatments. - Tailored therapy based on individual genetic mutations.
Original Abstract Submitted
the present invention relates to a method of identifying a metastatic tumor determined to have a mutation in homologous recombination pathway genes, that is sensitive to treatment with talazoparib, or a pharmaceutically acceptable salt thereof, and methods of treatment thereof, comprising a) determining a homologous recombination deficiency score from a biopsy of the metastatic tumor; and b) administering talazoparib, or a pharmaceutically acceptable salt thereof, if the homologous recombination deficiency score is at least 33%, wherein the mutation is not germline brca1 or germline brca2. the present invention also relates to a method of selecting a subject determined to have a metastatic tumor with a mutation in homologous recombination pathway genes, for treatment with talazoparib, or a pharmaceutically acceptable salt thereof.
